Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast
Source: SeekingAlpha
2026-02-04 02:09:13 ET
More on Astellas Pharma ADR
- Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
- Seeking Alpha’s Quant Rating on Astellas Pharma ADR
Read the full article on Seeking Alpha
For further details see:
Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.89% G/L:
$14.75 Last:
104,314 Volume:
$15.43 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
